Diabetes has emerged as a global health concern, with projections showing an increase to 11.3% in 2030 and 12.2% in 2045 worldwide.
In this scenario, Mexico stands out, ranking seventh in the world in diabetes cases, according to data from the International Diabetes Federation (IDF).
Alarmingly, 47.5% of patients in Mexico have not been diagnosed, signaling an important challenge in early detection.
The most affected states are Tabasco, Jalisco, and Puebla, evidencing a high incidence of Type 2 Diabetes Mellitus, the most common form of the disease.
Beyond the medical burden, associated complications, such as cardiovascular disorders and vision problems, significantly impact the financial stability of families and healthcare systems.
In the second quarter of this year, Sanofi reports 20,330 patient admissions with a diagnosis of Type 2 Diabetes Mellitus in Mexico.
Dr. María Elena Sañudo, medical director of the General Medicines Unit at Sanofi Mexico, underscores the importance of a comprehensive approach that encompasses promoting healthy lifestyles, education, and counseling on disease management.
Sanofi, committed to improving patients' quality of life, has developed technological tools such as "My Dose Coach" and "Delivering Health Patients" to offer support in diabetes monitoring and management.
The company seeks to facilitate treatment by integrating solutions from medical diagnosis to treatment access, promoting adherence and improving communication between doctors and patients.
Sanofi, aware of this challenge, works tirelessly to reinforce education about diabetes and promote a culture of awareness, with the goal of positively impacting the reduction of cases.
In a landscape where diabetes represents a growing burden, the integration of technological solutions and preventive strategies emerges as a crucial step toward a healthier future.
Source: Neo Health.
Receive all industry news in our weekly Scientific Dialectics Newsletter.